Patients with moderately-to-highly active Rheumatoid arthritis receive a 12-week VIB4920
treatment with Tumor necrosis factor alpha inhibitor (TNFi) compared to background
disease-modifying (RA) therapy with TNFi and without the addition of VIB4920. The primary
objective is to determine if the addition of a 12-week course of treatment with VIB4920 to a
TNFi in patients with RA who have had an inadequate response to a TNFi results in improved
clinical disease control.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)